There's a lot of news this year about pullback in valuations for biotechnology and digital health, and cutbacks in investments. See. for example, potential Nasdaq delisting for Centogene, here, and a 33:1 reverse stock maneuver for GeneDx (formerly Sema4), whose valuation has plummeted, here.
But there are some bright spots for investments as well, especially the continuing activity in the minimal residual disease space.
- Haystack, an MRD company, to be acquired by Quest for $300M-450M, here.
- Foresight Diagnostics closes a $60M investment round. Foresight is a Stanford-spinout in the MRD space, garners $60M in Series B, here.
- Earlier this month, Mercy BioAnalytics raised $40M in a Series A round, and picked up Myla Lai-Goldman as a board member; here, here.
Changing Payor Dynamics
A current article in CAP TODAY on comprehensive genomic profiling of tumors devotes a large amount of space to discussion of ongoing reimbursement woes - entry point here.
A current deep dive article in Genomeweb (subscription; Adam Bonislawski; 2000 words) talks about how the lab industry will navigate a new era of "value based purchasing" witih payors. Numerous interviews. Here.